Transversalis Fascia Plane Block and Rectus Sheath Block in Renal Transplantation Donors

Effects of Transversalis Fascia Plane Block and Rectus Sheath Block on Opioid Consumption in Renal Transplantation Donors

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05324215

Enrollment

Registered

2022-04-12

Start date

2022-02-17

Completion date

2023-02-17

Last updated

2022-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Pain

Brief summary

Transversalis fascia plane block (TFPB) is a relatively new, easy-to-apply and safe regional anesthesia technique used to provide postoperative analgesia in various surgeries. It has been shown that TFPB and rectus sheath block (RSB) administration reduces opioid consumption and related side effects in patients undergoing surgery with general anesthesia. To our knowledge, there is no study examining TFPB in donor nephrectomy. The investigators aimed to prospectively examine the effect of TFPB and RSB on opioid consumption in postoperative period on donors who will undergo laparoscopic nephrectomy in renal transplantation surgery.

Interventions

PROCEDURETransversalis fascia plane block and rectus sheath block

Transversalis fascia plane block and rectus sheath block will be administered after the surgery.

DEVICEIntravenous fentanyl patient control device

24-hour fentanyl consumption will be recorded.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Yes

Inclusion criteria

* Donor patients scheduled for elective nephrectomy in renal transplantation surgery * American Society of Anesthesiologists (ASA) I-II * Patients who are aged between 18-75

Exclusion criteria

* Skin infection at the block area * Coagulation disorder and using anticoagulant drugs * End-stage organ and system failure * Severe pulmonary and/or cardiovascular problems * Substance addiction or known psychiatric or mental problems * Chronic painkiller usage

Design outcomes

Primary

Measure	Time frame	Description
Total opioid consumption retrieved from patient records	up to 24 hours	the amount of fentanyl required by the patient and given by the device will be recorded for the first 24 hours.

Secondary

Measure	Time frame	Description
Numeric Rating Scale (NRS)	up to 24 hours	Pain of patients will be evaluated and recorded according to NRS. A NRS requires the patient to rate their pain on a defined scale between 0 and10 (0 is no pain and 10 is the worst pain)

Countries

Turkey (Türkiye)

Contacts

Primary ContactÖzlem Özkalaycı, MD

oozkalayci@kuh.ku.edu.tr+90 850 250 8250

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026